Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
NCT02690961Phase 1Completed
- Sponsor
- Tianjin Chase Sun Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of kukoamine B in sepsis (6 arms), sponsored by Tianjin Chase Sun Pharmaceutical. Primary endpoint: Incidence of adverse events at 14 days. Started Mar 2016; status: completed.
02
Drugs
kukoamine B
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02690961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690961.